| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11029185 | IJC Heart & Vasculature | 2018 | 5 Pages |
Abstract
These findings suggest that RV enlargement, which represents right-sided volume overload, elevated filling pressure, and diastolic dysfunction similar to that seen in constrictive pericarditis, predicts responsiveness to tolvaptan in patients with HFrEF. Moreover, administration of tolvaptan may have the potential to improve the reportedly poor prognosis for HFrEF patients with RV dilatation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Shinichi Nonin, Shinichi Iwata, Asahiro Ito, Soichiro Tamura, Ryoko Kitada, Yu Kawai, Sera Ishikawa, Atsushi Doi, Akihisa Hanatani, Minoru Yoshiyama,